Results 31 to 40 of about 104,116 (405)

Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009–2018

Drug and Alcohol Dependence Reports, 2023
Background: Although use of buprenorphine for treating opioid use disorder increased over the past decade, buprenorphine utilization remains limited in lower-income and rural areas.
Olivia K. Golan, Flora Sheng, Andrew W. Dick, Mark Sorbero, Daniel J. Whitaker, Barbara Andraka-Christou, Therese Pigott, Adam J. Gordon, Bradley D. Stein   +8 more
doaj   +1 more source

Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs

JAMA Health Forum, 2022
This cross-sectional study evaluates the changes in buprenorphine use for opioid use disorder among Medicaid enrollees in states that completely removed buprenorphine prior authorization requirements.
S. Keshwani, Michael Maguire, A. Goodin, W. Lo‐Ciganic, Debbie L. Wilson, J. Hincapie-Castillo   +5 more
semanticscholar   +1 more source

Buprenorphine reduces methamphetamine intake and drug seeking behavior via activating nociceptin/orphanin FQ peptide receptor in rats

Frontiers in Psychiatry, 2022
Buprenorphine, which has been approved for the treatment of opioid dependence, reduces cocaine consumption by co-activating μ-opioid receptors and nociceptin/orphanin FQ peptide (NOP) receptors. However, the role of buprenorphine in methamphetamine (METH)
Fangmin Wang, Fangmin Wang, Fangmin Wang, Wenwen Shen, Yujia Cai, Xin Zhang, Han Du, Miaojun Lai, Huifen Liu, Evelyne Kohli, Evelyne Kohli, Wenhua Zhou   +11 more
doaj   +1 more source

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use

JAMA Network Open, 2022
Key Points Question What is the prevalence and comparative effectiveness associated with buprenorphine and naltrexone in individuals with opioid use disorder (OUD) and cooccurring substance use disorders (SUDs)?
K. Xu, Carrie M. Mintz, Ned J. Presnall, L. Bierut, R. Grucza   +4 more
semanticscholar   +1 more source

The challenge of perioperative pain management in opioid-tolerant patients [PDF]

, 2017
The increasing number of opioid users among chronic pain patients, and opioid abusers among the general population, makes perioperative pain management challenging for health care professionals.
Bifulco, F, Coluzzi, Flaminia, Corcione, A., Cuomo, A, Dauri, M, Leonardi, C, Melotti, Rm, Natoli, S, Romualdi, P, Savoia, G   +9 more
core   +6 more sources

Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use

Addiction Science & Clinical Practice, 2023
Background We use a novel, longitudinal approach to describe average time spent in opioid use disorder (OUD) cascade of care stages for people with HIV (PWH) and with OUD, incorporating four definitions of treatment retention.
Jarratt D. Pytell, Anthony T. Fojo, Jeanne C. Keruly, LaQuita N. Snow, Oluwaseun Falade-Nwulia, Richard D. Moore, Geetanjali Chander, Catherine R. Lesko   +7 more
doaj   +1 more source

Single high-dose buprenorphine for opioid craving during withdrawal. [PDF]

, 2018
BackgroundOpioid use disorder is one of the most prevalent addiction problems worldwide. Buprenorphine is used as a medication to treat this disorder, but in countries where buprenorphine is unavailable in combination with naloxone, diversion can be a ...
Ahmadi, Jamshid, Ghahremani, Dara, Jahromi, Mina Sefidfard, London, Edythe D   +3 more
core   +2 more sources

Buprenorphine Telehealth Treatment Initiation and Follow-Up During COVID-19

Journal of general internal medicine, 2022
Opioid overdose deaths surged during the COVID-19 pandemic, increasing 30% in 2020 compared to 2019. Medications for opioid use disorder (MOUD) are one component of an evidence-based strategy to reduce opioid-related morbidity and mortality.
E. Samuels, U. Khatri, H. Snyder, R. Wightman, B. Tofighi, N. Krawczyk   +5 more
semanticscholar   +1 more source

Emergency Department Buprenorphine Quality Improvement and Emergency Physician Knowledge, Attitudes, and Self-Efficacy

Western Journal of Emergency Medicine, 2023
Objective: Buprenorphine is an evidence-based treatment for opioid use disorder that is underused in the emergency department (ED). In this study we evaluated changes in emergency physician knowledge, confidence, and self-efficacy regarding buprenorphine
Michelle L. Myles, Kelli Scott, Hannah N. Ziobrowski, Sarah A. Helseth, Sara Becker, Elizabeth A. Samuels   +5 more
doaj   +1 more source

Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine

JAMA Network Open, 2021
Key Points Question Are patient-reported outcomes, such as treatment satisfaction with medication, higher among patients treated with weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine?
N. Lintzeris, A. Dunlop, P. Haber, D. Lubman, Robert Graham, Sarah Hutchinson, Shalini Arunogiri, Victoria Hayes, P. Hjelmström, A. Svedberg, S. Peterson, F. Tiberg   +11 more
semanticscholar   +1 more source